Clinical Trials at Lahey Hospital and Medical Center
As of June 2026, 47 paid clinical trials are recruiting at Lahey Hospital and Medical Center in Burlington, Massachusetts. Active studies at this site cover conditions such as Breast Cancer, ARDS and Acute Respiratory Distress Syndrome. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
47 clinical trials at Lahey Hospital and Medical Center
·Clear filters·↓ Download CSVSDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
E-Mindfulness Approaches for Living After Breast Cancer
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
XACT ACE Observational Registry
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
About research studies in Burlington
Burlington has approximately 94 recruiting research studies across a wide range of therapeutic areas. Massachusetts is a global epicenter of biomedical research, anchored by Harvard-affiliated hospitals (MGH, Brigham and Women's, Dana-Farber), Boston Children's Hospital, and the Kendall Square biotech corridor in Cambridge.
Common conditions studied in Burlington
- Breast Cancer (8 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- ARDS (5 active studies). Recruiting ARDS studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Respiratory Distress Syndrome (5 active studies). Recruiting Acute Respiratory Distress Syndrome studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- ARDS (Acute Respiratory Distress Syndrome) (4 active studies). Recruiting ARDS (Acute Respiratory Distress Syndrome) studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Respiratory Distress Syndrome (ARDS) (4 active studies). Recruiting Acute Respiratory Distress Syndrome (ARDS) studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Atrial Fibrillation (4 active studies). Atrial fibrillation studies investigate next-generation anticoagulants, ablation technologies, and left atrial appendage closure devices.
Leading research sponsors in Burlington
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- NRG Oncology
- PPD Development, LP
- Alliance for Clinical Trials in Oncology
Local regulations and guidelines
Clinical trials in Massachusetts are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Massachusetts trials follow additional state privacy requirements enforced under 201 CMR 17.00 and oversight from the Massachusetts Department of Public Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Burlington. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Burlington
Hipa.ai aggregates every recruiting study in Burlington from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Burlington?
There are approximately 94 recruiting clinical trials in Burlington, Massachusetts listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Burlington pay participants?
Most recruiting trials in Burlington compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Burlington?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Burlington?
The most common conditions under active study in Burlington include Breast Cancer (8), ARDS (5), Acute Respiratory Distress Syndrome (5), ARDS (Acute Respiratory Distress Syndrome) (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Burlington?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Burlington on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Burlington?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Burlington?
Recruiting research sites in Burlington include Lahey Hospital and Medical Center, Lahey Hospital & Medical Center, 89bio Clinical Study Site, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Burlington right now?
The largest active categories in Burlington are Cancer & tumors (45), Cardiovascular (7), Neurology & pain (5). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.